Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Venlafaxine-associated vaginal bleeding.

Sunny A Linnebur1, Joseph J Saseen, Wilson D Pace

  • 1Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA. sunny.linnebur@uchsc.edu

Pharmacotherapy
|May 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same author

The 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia-Best evidence and practices aligned.

Journal of clinical lipidology·2026
Same author

New Dyslipidemia Guideline Expands Treatment Options and Risk Assessment in Patients With Diabetes and Chronic Kidney Disease.

Journal of the American College of Cardiology·2026
Same author

Importance of Residency Training for the Provision of Comprehensive Clinical Pharmacy Services.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Nonstatins for LDL-C lowering: An expansion whose time has come.

Journal of clinical lipidology·2026
Same author

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Venlafaxine, an antidepressant, may cause unexpected vaginal bleeding in women. This adverse effect was observed in a patient and is supported by broader surveillance data on antidepressant use.

Area of Science:

  • Pharmacology
  • Gynecology
  • Psychiatry

Background:

  • Antidepressants are widely prescribed for mood disorders.
  • Menstrual irregularities are potential side effects of some psychotropic medications.
  • Understanding drug-induced adverse effects is crucial for patient safety.

Observation:

  • A case of a 41-year-old woman experiencing amenorrhea (absence of menstruation) was reported.
  • The patient initiated venlafaxine (37.5 mg/day) for depression treatment.
  • Vaginal bleeding occurred seven days after starting venlafaxine and resolved upon discontinuation.

Findings:

  • Recurrence of vaginal bleeding was observed upon rechallenge with venlafaxine.
  • No prior published reports specifically linked venlafaxine to vaginal bleeding.

Related Experiment Videos

  • Existing surveillance data indicated similar adverse effects with venlafaxine.
  • Other antidepressants like fluoxetine and bupropion have been associated with menstrual irregularities.

    • Implications:

    • This case highlights a potential, previously unreported, adverse effect of venlafaxine.
    • Healthcare providers should be aware of the possibility of venlafaxine-induced vaginal bleeding.
    • Further investigation into the gynecological effects of venlafaxine and similar antidepressants is warranted.